Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile

RATIONALE: The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring rapid adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising treatment that can be mobilized rapidly in a pandemic s...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :medRxiv
Главные авторы: Sturek, Jeffrey M., Thomas, Tania A., Gorham, James D., Sheppard, Chelsea A., Raymond, Allison E., Guex, Kristen Petros De, Harrington, William B., Barros, Andrew J., Madden, Gregory R., Alkabab, Yosra M., Lu, David, Liu, Qin, Poulter, Melinda D., Mathers, Amy J., Thakur, Archana, Kubicka, Ewa M., Lum, Lawrence G., Heysell, Scott K.
Формат: Artigo
Язык:Inglês
Опубликовано: Cold Spring Harbor Laboratory 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7899478/
https://ncbi.nlm.nih.gov/pubmed/33619508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.02.16.21251849
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы